SCHEMBL95349

SCHEMBL95349

[CH2]c1ccc(NC(=O)C=Cc2ccc3c(c2)OCO3)cc1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 12/20 0.77
MAPT P10636 7/20 0.77
RAB9A P51151 10/20 0.72
ALDH1A1 P00352 9/20 0.72
SMN1; SMN2 Q16637 9/20 0.72
NPC1 O15118 8/20 0.72
MEN1 O00255 3/20 0.72
KMT2A Q03164 3/20 0.72
TRPV1 Q8NER1 2/20 0.65
HPGD P15428 4/20 0.64
CYP1A2 P05177 1/20 0.64
CYP3A4 P08684 1/20 0.64
CYP2C9 P11712 1/20 0.64
CYP2C19 P33261 1/20 0.64
PKM P14618 1/20 0.64
LMNA P02545 4/20 0.60
MAPK1 P28482 1/20 0.60
NFKB1 P19838 1/20 0.60
NFKB2 Q00653 1/20 0.60
RELA Q04206 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL95348 1.00 KDM4E (0.77) KDM4EMAPTRAB9AALDH1A1SMN1; SMN2
SCHEMBL109258 0.89 MAPT (0.81) KDM4EMAPTRAB9AALDH1A1SMN1; SMN2
SCHEMBL18993423 0.88 KDM4E (0.79) KDM4EMAPTRAB9AALDH1A1SMN1; SMN2
SCHEMBL22510789 0.88 KDM4E (0.79) KDM4EMAPTRAB9AALDH1A1SMN1; SMN2
SCHEMBL18027733 0.87 KDM4E (0.81) KDM4EMAPTRAB9AALDH1A1SMN1; SMN2
SCHEMBL9911665 0.87 KDM4E (0.77) KDM4EMAPTRAB9AALDH1A1SMN1; SMN2
SCHEMBL21998487 0.86 MAPT (0.76) KDM4EMAPTRAB9AALDH1A1SMN1; SMN2
SCHEMBL13675911 0.86 TRPV1 (0.75) KDM4EMAPTRAB9AALDH1A1SMN1; SMN2
SCHEMBL21998488 0.85 KDM4E (0.78) KDM4EMAPTRAB9AALDH1A1SMN1; SMN2
SCHEMBL21998490 0.85 TRPV1 (0.80) KDM4EMAPTRAB9AALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362252-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-01-29 US disclosed
EP-1797082-B1 CARBOSTYRIL COMPOUND OTSUKA PHARMA CO LTD (JP) 2012-08-29 EP disclosed
EP-2426128-A1 Carbostyril compound Otsuka Pharmaceutical Co., Limited (JP) 2012-03-07 EP disclosed
US-20100261705-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. 2010-10-14 US disclosed
US-7777038-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-08-17 US disclosed
US-20090326008-A1 NF-kappa B Inhibitor OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2009-12-31 US disclosed
US-20070179173-A1 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-02 US disclosed
EP-1797082-A1 CARBOSTYRIL COMPOUND Otsuka Pharmaceutical Company, Limited (JP) 2007-06-20 EP disclosed
WO-2006035954-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-04-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090326008-A1 NF-kappa B Inhibitor NFKBIA, NFKB2, IKBKB KDM4E 1125/4885MAPT 4112/4885RAB9A 3886/4885
US-20070179173-A1 Carbostyril compound GTF2F1, F3, GTF2F2 KDM4E 3919/4885MAPT 4773/4885RAB9A 2273/4885
US-20100261705-A1 CARBOSTYRIL COMPOUND GTF2F1, F3, GTF2F2 KDM4E 3919/4885MAPT 4773/4885RAB9A 2273/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.